Haleon said on Tuesday it had rejected requests to provision for costs related to US lawsuits over the heartburn drug Zantac, its latest pushback against a threat that has hung over the FTSE 100 consumer health company since it was spun off from GSK in July. GSK and Pfizer, partners in the joint venture that … Read more
In January, the United Kingdom pharmaceutical firm GSK turned down Unilever offer of 50 billion pounds sterling, or about $60 billion, to buy its consumer healthcare division, saying the price was too low. Six months later, the former division is a stand-alone public company called Haleon (ticker: HLN), with a market value of £24 billion, … Read more
Pharmaceutical stocks GSK (GSK), Sanofi (SNY) and Haleon (HLN) extended deep losses Thursday as worries mount surrounding litigation around recalled heartburn drug Zantac. X The companies are among the defendants in a series of lawsuits claiming Zantac contains a cancer-causing substance called NDMA. The first trial is set to begin this month in Illinois and, … Read more
European-listed shares of drugmakers Haleon HLN, -5.30%, GSK GSK, -7.95% and Sanofi SAN, -8.77% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. GSK shares dropped 10% in London, as Sanofi and Haleon also dropped sharply. Analysts at Deutsche Bank said they don’t … Read more
This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds" Source link